The size of the North American IVF market is expected to be worth USD 1.20 billion by 2028 from USD 1.02 billion in 2022, growing at a CAGR of 16.2% between 2023 to 2028.
The IVF (In Vitro Fertilization) market in North America is expected to be driven by an increase in the number of fertility clinics and infertility services and increased product launches due to government support. The key drivers predicted to drive the IVF market's development in the North American region include an increase in the median age of first-time motherhood, falling fertility rates, rising male infertility, rising alcohol and cigarette usage, newly opened fertility facilities, and reimbursement policies for infertility treatment and increased public awareness about infertility and treatment alternatives. In addition, the market for fertility therapy is expected to expand in health because of the large patient population, growing product launches, the presence of strong market players, and rising government support.
Improved progressive motility, a greater proportion of normal morphology, better fertilization rates, and higher euploidy and pregnancy rates result from healthier sperm. The better results related to these gadgets could drive up demand in the future. In addition, increased awareness of sophisticated in vitro fertilization (IVF) procedures, increased IVF success rates, and diseases caused by the delayed beginning of pregnancy have all boosted the demand for IVF techniques in this region. The key measures activating a woman's ovulatory system, extracting an ovum from her ovaries, and fertilizing the ovum with sperm in a laboratory liquid. IVF is one of the most often utilized procedures to help couples with infertility difficulties, a major driver driving the IVF services market. Cultural change, which includes factors such as an increase in the number of women in the workforce, an increase in the age at which women have their first child, a steady shift from rural to urban communities, and lower marriage rates, is one of the primary causes of reduced Total Fertility Rate (TFR). On the other hand, advances in IVF therapies have brought up new prospective opportunities and favorable outcomes from diverse procedures.
The growth of the North American IVF market is likely to be hampered by the high procedure costs of assisted reproductive technologies and problems connected with IVF and the associated socio-ethical considerations. In addition, the high cost and difficulties of IVF therapy and a lack of knowledge about IVF in some areas are challenging the growth of the North America IVF market.
This research report on the North American IVF Market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By End Users:
Geographically, the North American IVF market is forecasted to account for a significant share of the global market during the forecast period. Because of the growing frequency of related diseases such as Polycystic Ovary Syndrome, the In Vitro Fertilization market in North America is projected to develop significantly (PCOS). In addition, the research market in the area is expected to be driven by a steady rise in the incidence of infertility in both sexes. The growth in male infertility is expected to boost IVF treatment adoption and, as a result, accelerate the in vitro fertilization market size in the future years. Aside from that, government-backed reimbursement regulations and public awareness campaigns assist the region's overall in vitro fertilization industry growth.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the North American IVF Market profiled in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.)
RECENT MARKET HAPPENINGS:
February 2018: In-vitro fertilization-focused machine learning company Univfy has raised USD 6 million in Series funding. Univfy developed machine learning technology, which aims to reduce the financial burden on those affected by infertility.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org